Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by CIBC Asset Management Inc

Share on StockTwits

CIBC Asset Management Inc reduced its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.4% in the 1st quarter, Holdings Channel reports. The institutional investor owned 53,218 shares of the biopharmaceutical company’s stock after selling 4,246 shares during the period. CIBC Asset Management Inc’s holdings in Alexion Pharmaceuticals were worth $7,194,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Investors Research Corp purchased a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at approximately $27,000. Captrust Financial Advisors acquired a new stake in shares of Alexion Pharmaceuticals during the 4th quarter valued at approximately $31,000. Whittier Trust Co. raised its position in shares of Alexion Pharmaceuticals by 20.4% during the 1st quarter. Whittier Trust Co. now owns 472 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 80 shares in the last quarter. NuWave Investment Management LLC raised its position in shares of Alexion Pharmaceuticals by 851.9% during the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 460 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC acquired a new stake in shares of Alexion Pharmaceuticals during the 1st quarter valued at approximately $74,000. Institutional investors own 94.82% of the company’s stock.

Several equities research analysts recently issued reports on ALXN shares. Cowen reissued a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 13th. Credit Suisse Group reissued a “buy” rating and set a $156.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, January 22nd. Morgan Stanley upped their price target on Alexion Pharmaceuticals from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Tuesday, February 12th. Raymond James upped their price target on Alexion Pharmaceuticals from $161.00 to $164.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. Finally, Guggenheim reissued a “neutral” rating and set a $135.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, March 21st. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $162.25.

Shares of NASDAQ ALXN opened at $126.26 on Wednesday. Alexion Pharmaceuticals, Inc. has a 1-year low of $92.56 and a 1-year high of $141.86. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $28.24 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 0.99 and a beta of 1.53.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.99 by $0.40. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the company earned $1.68 earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. Sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.6 EPS for the current fiscal year.

In other news, CAO Daniel Bazarko sold 2,000 shares of the firm’s stock in a transaction on Thursday, February 14th. The stock was sold at an average price of $126.00, for a total transaction of $252,000.00. Following the transaction, the chief accounting officer now directly owns 5,020 shares of the company’s stock, valued at $632,520. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.08% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by CIBC Asset Management Inc” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://weekherald.com/2019/05/15/alexion-pharmaceuticals-inc-alxn-shares-sold-by-cibc-asset-management-inc.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.